The apartment rental services provider, which counts Ant Financial, UCommune and Bertelsmann as investors, has filed for a $100m IPO on the New York Stock Exchange.

The Takeda-backed gastrointestinal disease therapy developer has boosted its initial public offering to $209m after its shares rose 23% post-flotation.

Xiaomi is set to achieve an exit after audio content platform Lizhi filed for an initial public offering in the US that is slated to raise up to $100m.

The Novo and Novartis-backed company, which is developing drugs to make radiotherapy less harmful, is set to raise between $70m and $80m.

Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.

GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

Intel Capital portfolio company Schoology has been picked up by PowerSchool, which will integrate the cloud-based curriculum management software platform with its Unified Classroom service.

Dahong Group, Junfa Group, Prosperity Holdings and Yintai Land are all in line for exits after the workspace provider confidentially filed for an initial public offering in the US.

Intel Capital, Samsung Catalyst Fund and National Grid Partners are all set to exit the edge computing technology developer in a purchase of undisclosed size.

The Celgene and GV-backed cancer and atopic dermatitis drug developer is now targeting $75m in an initial public offering it postponed in August.